The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Relapse after HSCT 2021 | Management of relapse after CAR-T in patients with B-cell lymphoma

Name: Management of relapse after CAR-T in patients with B-cell lymphoma
Uploaded: 2021-10-05T00:00:00Z
Duration: 1 min 33 s
Description: Peter Dreger, MD, Heidelberg University Hospital, Heidelberg, Germany, describes the management of patients with B-cell lymphomas relapsing following treatment with CD19-targeted chimeric antigen receptor (CAR) T-cells, commenting on the role of allogeneic hematopoietic stem cell transplantation. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.

Peter Dreger • 5 Oct 2021

Relapse after HSCT 2021

B-Cell Lymphoma Lymphoma CAR-T

Peter Dreger, MD, Heidelberg University Hospital, Heidelberg, Germany, describes the management of patients with B-cell lymphomas relapsing following treatment with CD19-targeted chimeric antigen receptor (CAR) T-cells, commenting on the role of allogeneic hematopoietic stem cell transplantation. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.